A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis

Clinical trial NCT02899988 · COMPLETED

Trial details

NCT number: NCT02899988
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Plaque Psoriasis

Start date: 2016-09-14
Primary completion: 2017-06-19
Enrollment: 205

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.